Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895566 | 0.86 | MAPT (0.66) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL6661349 | 0.80 | MAPT (0.57) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL6661714 | 0.80 | MAPT (0.57) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL1050030 | 0.77 | MAPT (1.00) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL29361322 | 0.77 | MAPT (1.00) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL29438168 | 0.76 | MAPT (0.71) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL42481 | 0.76 | MAPT (0.71) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL11306687 | 0.76 | MAPT (0.71) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| SCHEMBL11167085 | 0.76 | MAPT (0.71) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR | |
| Hydrochloric Acid SCHEMBL30287663 | 0.75 | MAPT (0.96) | MAPTMAPK1SMN1; SMN2L3MBTL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | MAPT 4879/4885MAPK1 4087/4885SMN1; SMN2 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.